![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CELLULAR AND MOLECULAR
Henry Ford Hospital, Detroit, Michigan (A.M.G., J.S., G.M.S., A.S.A., N.L.L., P.A.E., A.G.S.); University of Texas Southwestern Medical Center, Dallas, Texas (J.R.F.); Medical College of Wisconsin, Milwaukee, Wisconsin (R.J.R.); and Henry Ford Hospital and Wayne State University, Detroit, Michigan (A.G.S.)
Received for publication
May 13, 2008
Accepted
June 27, 2008.
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
10-fold larger tumor volume (10 days postimplantation) compared with animals receiving mock-transfected U251 cells. These data show that elevations in 20-HETE synthesis in U251 cells lead to an increased growth both in vitro and in vivo. This suggests that 20-HETE may have proto-oncogenic properties in U251 human gliomas. Further studies are needed to determine whether 20-HETE plays a role promoting growth of some human gliomas.
; Roman, 2002; Sacerdoti et al., 2003; Zhao and Imig, 2003; Liang et al., 2008). The major isoforms involved in 
-hydroxylation of AA to 20-HETE are enzymes of the 450 4A (CYP4A) and CYP4F families. 20-HETE is a potent mitogen in a variety of cell types and has also been reported to serve as a second messenger in the mitogenic actions of a number of growth factors (Sun et al., 1999). However, the signal transduction pathways that mediate the effects of 20-HETE on cellular proliferation remain to be fully elucidated.
Cancer cells produce a wide variety of growth factors that contribute to their abnormal growth phenotype both in vitro and in vivo (Hoelzinger et al., 2007). Gliomas are the most common primary brain tumor in humans. Treatment of brain tumors, particularly glioblastoma, represents a considerable clinical challenge because they are resistant to conventional treatments, such as radiation and chemotherapy. Very little is known about the molecular pathways involved in glioma cell proliferation and survival. It would be important to understand which factors can regulate glioma cells growth. Brain vascular cells generate 20-HETE (Gebremedhin et al., 2000); in a recent study, we reported that the brain parenchyma tissue also produces substantial amounts of 20-HETE when incubated with AA (Guo et al., 2005b). Astrocytes are capable of playing a part in glioblastoma multiform invasion and are now known to generate 20-HETE, which contributes to neurovascular regulation (Metea and Newman, 2006, 2007; Gordon et al., 2007). Thus, tumors are normally exposed to 20-HETE generated from multiple sources in the brain. The National Cancer Institute database, named REMBRANDT (REpository for Molecular BRAin Neoplasia DaTa) (https://caintegrator.nci.nih.gov/rembrandt), indicates that a subpopulation of brain tumors taken from patients express enzymes known to produce 20-HETE.
We previously reported that 20-HETE induces proliferation in U251 cells and in 9L rat gliosarcoma cells in vitro. These data suggest that 20-HETE and/or its metabolic products are capable of regulating growth in human glioma cancer cells. However, exogenous addition of a compound as a single high dose is unlikely to reflect in vivo conditions, in which growth factors may be present as a continuous supply. Furthermore, exogenous addition of 20-HETE may mimic paracrine or autocrine effects. However, 20-HETE synthases are microsomal; thus, the bulk of the effects of 20-HETE may be intracrine.
We hypothesized that inducing stable expression of a 20-HETE synthase enzyme and thus 20-HETE in a human glioma cell line, U251, would alter the growth rate of these cancer cells both in vitro and in vivo. To test this hypothesis, we established a U251 cell line, termed U251 O, which stably expresses CYP4A1, a potent 450 isoform that selectively metabolizes AA to 20-HETE (Nguyen et al., 1999). We found that CYP4A1–20-HETE expression resulted in marked up-regulation of proliferation, increase in oxidative stress, marked changes in cell morphology, increases in VEGF in vitro, and marked acceleration of the growth of tumors derived from these cells in vivo.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
CYP4A1 expression was confirmed by Western blot analysis and by measuring the production of 20-HETE in the cell homogenates. To measure 20-HETE synthase activity, control and transfected cells were harvested, homogenized in 0.1 M phosphate buffer, and the protein concentrations were measured. One milligram of homogenate protein was incubated with a saturating concentration of arachidonic acid for 1 h in the presence of 1 mM NADPH. The incubations were stopped by acidification to pH 3.5 with formic acid, homogenized, and the homogenate was extracted twice with 3 ml of ethyl acetate after the addition of 2 ng of an internal standard, d6-20-hydroxyeicosatetraenoic acid. The organic phase was collected and dried under nitrogen. The samples were reconstituted with 50% methanol and water, and the metabolites were separated by high-performance liquid chromatography on a Betabasic C18 column (150 x 2.1 mm, 3 µm; Thermo Electron Corporation, Belletonte, PA) at a flow rate of 0.2 ml/min using an isocratic elution starting from a 51:9:40:0.01 mixture of acetonitrile/methanol/water/acetic acid for 30 min followed by a step change to 68:13:19:0.01 acetonitrile/methanol/water/acetic acid and water for 15 min. The effluent was ionized using a negative ion electrospray and the peaks eluting with a mass/charge ratio of 319 > 301 (HETEs and epoxyeicosatrienoic acids), 337 > 319 (DiHETEs), or 323 > 270 (internal standard) were monitored using an Applied Biosystems 3000 triple quadrupole mass spectrometer (Foster City, CA). The ratios of ion abundance amount in the peaks of interest versus those seen in the internal standard were determined and compared with standard curves generated over a range from 0.1 to 2.0 ng for 20-HETE and from 1.0 to 10 ng for the other metabolites. Values are expressed as picomoles of product formed per minute per milligram of protein.
siRNA Silencing of CYP4A1 in U251 Cells Overexpressing CYP4A1. CYP4A1 overexpression in U251 O was silenced using two sets of Silencer select predesigned CYP4A1 siRNA sequence primers (s139246 and s139248; Ambion, Austin, TX). Cells were transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. In brief, CYP4A1 targeted and control siRNA sequences were mixed with Lipofectamine 2000 reagent and added to U251 O cells at a final concentration of 10 nM for 8 h at 37°C. Cultures were then incubated for an additional 48 h before the proliferation experiments were performed.
Cell Proliferation Assays. Cell proliferation studies were performed as described previously (Guo et al., 2005a,b). The cells were plated at a density that ensured exponential growth for at least 5 days (5.0 x 104 cells) and grown in DMEM containing 10% heat-inactivated fetal bovine serum plus 1% streptomycin/penicillin and 1% nonessential amino acids (Invitrogen). Two highly selective inhibitors of the synthesis of 20-HETE, HET0016 (10 µM), and N-methylsulfonyl-12,12-dibromododec-11-enamide (DDMS; 20 µM) siRNA against CYP4A1 or a 20-HETE antagonist, 20-HEDE (10 µM), which has been reported to antagonize the vasoconstrictory, and other actions of 20-HETE or vehicle (ethanol) were added separately to the cultures. The concentration of ethanol added never exceeded 0.1%. After 48 h, the cells were harvested by exposure to 0.25% trypsin/EDTA and counted in triplicate using a hemocytometer.
Cell Detachment Assay. Cells were plated in 60-mm dishes, exposed to 0.005% trypsin/EDTA, and then the cultures were observed every minute. The time in minutes needed to observe complete detachment of the cells from the plate surface was recorded.
Flow Cytometry. U251 and U251 O were cultured in 100-mm dishes at densities that ensured exponential growth at the time of harvest. The harvesting and processing protocols used to detect DNA by flow cytometry with propidium iodide have been described by Reiners et al. (1999). Cells were analyzed with a BD Biosciences FACScan (BD Biosciences, San Jose, CA) at the Institute of Environmental Health Sciences Flow Cytometry Core Facility (Wayne State University, Detroit, MI). The percentages of cells in the G0/G1, S, and G2/M stages of the cell cycle were determined with a DNA histogram-fitting program (ModFit; Verity Software House, Topsham, ME). A minimum of 104 events/sample was collected.
Western Blotting. Protein extracts were harvested from U251 and U251 O. Western blot was performed as described previously (Guo et al., 2005a,b). In brief, cells were lysed using radioimmunoprecipitation assay buffer [20 mM HEPES, pH 7.4, 100 mM NaCl, 1% Nonidet P-40, 0.1% SDS, 1% deoxycholic acid, 10% glycerol, 1 mM EDTA, 1 mM NaVO3, 50 mM NaF, and protease inhibitors set 1 (Calbiochem, San Diego, CA)]. The cell lysates were centrifuged for 10 min at 14,000g at 4°C. The protein concentration of the supernatant was determined, and protein lysate (15–20 µg) was separated on 8 to 16% Tris-glycine gel and transferred to a polyvinylidene difluoride membrane. The membranes were incubated with primary antibodies in blocking buffer overnight at 4°C, washed, and incubated for 1 h at room temperature with a peroxidase-conjugated secondary antibody and developed using an enhanced chemiluminescence kit (Pierce Chemical, Rockford, IL) and Bio-Rad Gel Documentation system (Bio-Rad, Hercules, CA). The primary antibodies were anti-CYP4A1 (Daichi), anti-extracellular signal-regulated kinase (ERK) 1/2, anti-cyclin D1/2 (Millipore, Billerica, MA), and anti-VEGF165 (Millipore Bioscience Research Reagents, Temecula, CA). The membranes were stripped and reprobed with actin primary antibody (Santa Cruz Biochemicals, Santa Cruz, CA) that served as a loading control.
|
as described previously (Guo et al., 2007). Equal numbers of cells were plated in 12-well plates and allowed to grow overnight. Cultures were then placed in sterile Dulbecco's phosphate-buffered saline (Mediatech, Herndon, VA) containing 100 mg/l Ca2+ and Mg2+, 0.1% D-glucose, 50 µM L-arginine, and 100 µM NADPH for 20 min followed by the addition of 2 µM DHE. After an additional 30-min incubation, fluorescent images were obtained with a 20x objective using identical exposure times (2 s) with an inverted Leica immunofluorescence microscope (Leica, Wetzlar, Germany) with an excitation filter of 535 ± 25 nm and an emission filter of 610 ± 25 nm. The images were acquired for an average of 1 s using a spot digital camera and software.
Focal Adhesion and Morphological Assessment. U251 and U251 O cells plated in 12-well culture plates were double stained for focal adhesion and F-actin according to the manufacturer's recommended protocol. In brief, cells were fixed with 4% paraformaldehyde in phosphate-buffered saline for 15 min and then permeabilized with 0.1% Triton X-100 for 5 min. Cells were washed and blocked with 1% bovine serum albumin in phosphate-buffered saline. Cells were incubated with anti-vinculin antibody (1:1000; Millipore Corporation, Billerica, MA), followed by incubation with goat-anti-rabbit horse-radish peroxidase-conjugated secondary antibody (1:3000) and tetramethylrhodamine B isothiocyanate-conjugated phalloidin (1:500) for 30 min at room temperature. The cells were stained for 
-tubulin as we have previously described using FITC-conjugated anti--tubulin IgG (Guo et al., 2005a,b). The nuclei were counterstained by incubating the cells with DAPI for 2 min at room temperature and mounted on a slide with antifade mounting solution source. Cytoskeletal elements were visualized with a Leica fluorescence inverted microscope using an excitation/emission of 480 ± 20/535 ± 25 nm. The images were acquired using a spot digital camera and overlaid using Image-Pro Express 6.0 software (Media Cybernetics, Inc., Bethesda, MD).
Growth of U251 and U251 O Tumors in Vivo. Experimentally induced brain tumors were established by injecting mock-transfected U251 and U251 O cell suspensions into the cerebral cortex of nude rats. All animal studies were approved by an institutional animal care and user committee. Adult female nude rats (rnu/rnu), purchased from the National Institutes of Health, were anesthetized with an i.p. injection of 0.5 ml of 0.9% NaCl containing 100 mg/kg ketamine and 15 mg/kg xylazine. The surgical zone was swabbed with Betadine solution, the eyes were coated with Lacri-lube, and the animal was immobilized in a small animal stereotactic device (David Kopf Instruments, Tujunga, CA). After draping, a 1-cm incision was made 2 mm to the right of the midline 1 mm retro-orbitally, the skull was exposed with cotton-tip applicators, and an HP-4 dental drill bit was used with a micromanipulator to drill a hole (1 mm in diameter), 3 mm to the right and 2.5 mm anterior of the bregma, taking care not to penetrate the dura.
Immediately before implantation, the cell cultures were trypsinized and resuspended in serum-free DMEM without additional supplements. A 10-µl Hamilton syringe with a no. 4 point, 26-gauge needle containing tumor cells was inserted 3.5 mm into the cerebral cortex, then raised to a depth of 2.5 mm and 4 x 105 cells in 5 µl of medium (either mock-transfected U251 or U251 O) were injected at a rate of 0.5 µl/30 s until the entire volume was injected. If reflux was noted from the injection site, the animal was discarded. After completing the injection, we waited 2 to 3 min before withdrawing the needle. The hole in the skull was sealed with bone wax, and the skin was sutured over the incision site. The tumors were allowed to grow for 10 days before analyzing tumor volume by MRI.
|
MRI Image Analysis. Signal intensities (SIs) of the tumors and the normal brains were determined by hand-drawn ROI around the tumors and the contralateral hemispheres from T1-weighted images using image analysis software (Eigentool image analysis software developed at the Radiology Image Analysis Laboratory of the Henry Ford Health System; http://www.radiologyresearch.org/eigentool.htm). Signal intensities were determined from consecutive images containing tumors. Percent intensity change in the tumors compared with contralateral hemispheres was calculated as follows: (mean SI of tumor/mean SI of contralateral brain) x 100. The values were calculated for every section that contained tumor and averaged together. An operator blind to the animal groups drew and calculated the values. Likewise, tumor volume was also calculated by drawing ROI around the tumors from all images containing tumors.
Tumor Processing. Tissue was harvested immediately after the MRI analysis from the animals implanted with U251 O (10 days after implantation) and from the animals with mock-transfected U251 (18 days after implantation). The animals were euthanized with 150 to 200 mg/kg pentobarbital and perfused with 100 ml of saline and 100 ml of 2.5% paraformaldehyde intracardiacally, given at 5 ml/min. The brain was collected, and immersion was fixed in 4% paraformaldehyde and 3% sucrose. The brains were sectioned using a cryostat and 20 µm sections stained with hematoxylin and eosin for histological analysis.
Statistical Analysis. The significance of differences in mean values was analyzed using analysis of variance followed by Tukey's post hoc test or a Student's t test when only two groups were compared. A p value < 0.05 was considered to be significant.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Comparison of the Growth of U251 and U251 Cells Overexpressing CYP4A1 in Vitro. We found that expression of CYP4A1 in U251 O cells was associated with a hyperproliferative state. U251 O showed an almost 2-fold higher proliferation rate compared with mock-transfected U251 (p < 0.01) over a 3-day period (Fig. 2A). Flow cytometric analysis of the cell cycle suggested that this was due to an increased number of cells in the S phase (29 ± 1.55 versus 39 ± 1.53%, p < 0.01, U251 versus U251 O) (Fig. 2C). HET0016, a selective inhibitor of the formation of 20-HETE, completely abolished the increased S phase in the cell cycle and the increased proliferation of the U251 O (Fig. 2, B and C). Likewise, DDMS, a structurally different CYP4A1 inhibitor, also markedly decreased the proliferation of U251 O (Fig. 2B), whereas administration of 20-HEDE, a potent putative 20-HETE antagonist, for 48 h had no effects on the growth of U251 cells but completely abolished the hyperproliferation of U251 O (Fig. 2B).
To further confirm that the hyperproliferation of U251 O is specifically caused by increased CYP4A1 expression, siRNA against CYP4A1 was used to transfect U251 O. We found that CYP4A1 siRNA decreased CYP4A1 protein expression drastically in U251 O (Fig. 3A) and was associated with a significant decrease in the proliferation (Fig. 3B).
|
-tubulin staining indicated that the cytoskeleton of U251 O cells was disrupted and disorganized compared with mock-transfected U251 cells. We also found that U251 O had significantly reduced and dispersed immunoreactivity to vinculin, suggesting a loss of points of focal adhesion (Fig. 4). U251 O also exhibited decreased cell adhesion in culture, and significantly less time was required for U251 O cells to detach from the growth surface when exposed to a low concentration of trypsin (15 ± 2.5 min for U251 O to detach versus 38 ± 3 min for U251 control cells; data not shown).
|
Effects of CYP4A1 Expression on Oxidative Stress. Superoxide production was compared between U251 and U251 O cells by measuring changes in DHE fluorescence (Fig. 5A). U251 O cells exhibited marked (at least 4–5-fold) increases in DHE fluorescence compared with mock-transfected U251. To determine whether the increase in oxidative stress contributes to the hyperproliferation seen in U251 O cells, we examined the effects of adding 200 U/ml PEG-SOD (Fig. 5B). Addition of PEG-SOD to the media reduced the proliferation rate of both control and U251 cells expressing CYP4A1, but the effect was much greater in the U251 O cells with increased oxidative stress (Fig. 5B). In contrast, treatment with PEG-catalase had no effects (data not shown).
|
was undetectable in all U251 cells (data not shown). Blockade of the synthesis of 20-HETE with HET0016 prevented up-regulation of the expression of ERK1/2, cyclin D1/2 and VEGF in the U251 O cells expressing CYP4A1.
|
Mechanisms Involved in the Proliferative Effects of 20-HETE in U251 Cells Overexpressing CYP4A1. To further examine the mechanisms by which 20-HETE and oxidative stress induces cell proliferation, we examined the effects of U0126, a mitogen-activated protein kinase kinase-1 inhibitor, on the growth of U251 O cells. We found that U0126 (10 µM) abolished the increased phosphorylation of ERK1/2 (Fig. 7A) and the hyperproliferation of U251 O (Fig. 7B). To examine whether activation of ERK1/2 precedes or is caused by the increases in oxidative stress, these experiments were repeated using the superoxide-metabolizing enzyme, PEG-SOD. Administration of PEG-SOD (200 U/ml) had no effects on the phosphorylation of ERK1/2.
|
|
|
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
; Metea and Newman, 2006; Gordon et al., 2007; Medhora et al., 2007b). We have shown that the addition of a single dose of a 20-HETE analog to the cell media transiently stimulates the proliferation of U251 human glioma cells in vitro (Guo et al., 2005a,b). Exogenous 20-HETE may mimic autocrine or paracrine effects of the compound. However, 20-HETE synthases are microsomal enzymes and thus release 20-HETE intracellularly. In cell cultures, it is difficult to study the role of AA -hydroxylases in regulating cell functions because they are down-regulated. In U251, the mRNA coding for CYP4A11 is only detectable after 30 cycles of reverse transcriptase-polymerase chain reaction (Guo et al., 2005a).
We used U251 cells to explore the hypothesis that continuous and high production of 20-HETE would alter the growth rate of these cells. We compared mock-transfected U251 cells with cells transfected with a full-length rat CYP4A1 cDNA (termed U251 O). Although CYP4A1 is a rat enzyme, it has a high degree of homology with its human counterpart, CYP4A11 (Graham et al., 2006), and it has the advantage of being a potent 20-HETE synthase while having negligible ability to form epoxides (Nguyen et al., 1999; Medhora et al., 2007a). Thus, using CYP4A1 enabled us to clearly attribute the effects to 20-HETE.
The U251 O cells had more than 2-fold increases in proliferation rate and more cells entering the S phase of the cell cycle than mock-transfected cells, suggesting enhanced DNA replication. The elevated proliferation rate was abolished by treatment of the cells with a selective inhibitor of the synthesis of 20-HETE by inhibiting CYP4A1 synthesis with siRNA against CYP4A1 and by 20-HEDE, an antagonist of the biological actions of 20-HETE (Yu et al., 2004). These results demonstrated that the enhanced proliferation in U251 O was due to the high 20-HETE synthase activity.
We found that U251 O cells had profound alterations in their cytoskeleton. These cells also detached more easily from the basement matrix. A major component of the focal adhesion complex is vinculin that provides mechanical coupling between the integrins and the cytoskeleton. We found that the expression of immunoreactive vinculin was markedly reduced on the cell surface of U251 O compared with control cells, perhaps explaining their decreased adhesion.
U251 O had significantly higher levels of superoxide compare with U251 control cells. The increased proliferation rate of the U251 O requires superoxide, but not H2O2 because it was abolished by treatment with PEG-SOD, but not with PEG-catalase. This suggests that the redox imbalance caused by expression of CYP4A1–20-HETE also caused signals that directed the glioma cell line to greatly increase proliferation. This is consistent with the accumulating evidence suggesting that high 20-HETE might be associated with increased superoxide formation and changes in cell function (Guo et al., 2007; Cheng et al., 2008; Medhora et al., 2008; Nilakantan et al., 2008).
Interestingly, we observed no morphological evidence of apoptosis or necrosis in U251 cells expressing CYP4A1, even though these processes are activated in some cells by increased oxidative stress (Ueda et al., 2002; Pelicano et al., 2004). We cannot exclude the possibility that 20-HETE may act inhibiting apoptosis.
The cellular responses to oxidative stress are complex and often involve multiple signaling pathways. Oxidants can trigger phosphorylation cascades that are causally involved in the cell responses. U251 O would show chronic changes in these phosphorylation cascades because the cells are responding to constitutive and long-lasting changes in CYP4A1-derived products and ROS. The Ras-dependent ERK1/2 of the mitogen-activated protein kinase pathway is one of the key signal transduction pathways that regulate cell proliferation. ERK1/2 phosphorylate a vast array of substrates localized in all cellular compartments (Yoon and Seger, 2006). Growth effects of ROS may involve modifications of the MAPKs (Meloche and Pouyssegur, 2007). We found that U251 O cells had marked increases in phosphorylated ERK1/2. Furthermore, inhibition of ERK1/2 activation with the mitogen-activated protein kinase kinase-1 inhibitor U0126 halted the increased proliferation of U251 O. These findings suggest that the hyperproliferative effects of CYP4A1 expression are associated with the activation of the MAPK pathway through increased phosphorylation of ERK1/2 by 20-HETE. It is interesting to note that the increases in phosphorylated ERK1/2 were little affected by treatment with either PEG-SOD or Tempol (an SOD mimetic; data not shown). These results suggest that expression of CYP4A1–20-HETE alters cell growth in U251 human gliomas by a mechanism that initially involves activation of the ERK1/2 and then causes increases in ROS, which in turn trigger changes in cell proliferation. In endothelial cells, the effects of 20-HETE also require ERK1/2 activation (Guo et al., 2007), suggesting that increased superoxide and MAPK activation are common pathways whereby high 20-HETE might influence cell growth and function.
In response to mitogenic factors, D-type cyclins progressively accumulate during the G1 phase and assemble with their catalytic partners, Cdk4 and Cdk6 (Malumbres and Barbacid, 2005). U251 O also had markedly elevated concentrations of D1/2 cyclase, suggesting that activation of ERK1/2 resulted in accumulation of D-type cyclins because it is known to occur in cells progressing from the G1 to the S phase of the cell cycle (Malumbres et al., 2004). Further studies will be needed to determine whether the increases in D-type cyclins are involved in the hyperproliferative phenotype induced by high 20-HETE.
The growth and invasiveness of malignant glial tumors are markedly dependent on the process of neovascularization (angiogenesis), which is thought to be driven mainly by VEGF (Jain et al., 2007; Peddinti et al., 2007). We found that U251 O had high VEGF levels. This was not secondary to up-regulation of the known VEGF regulator hypoxia-inducible factor-1 because this factor was not detectable either in control U251 or U251 O. This fact suggests that 20-HETE is a nonhypoxic regulator of VEGF in human glioma cells, as we have shown in endothelial cells (Guo et al., 2007). Thus, the expression of CYP4A1–20-HETE induces hyperproliferation and enhanced VEGF, both features that are often found in aggressive human brain tumors (Jain et al., 2007).
To determine whether U251 O induces brain tumors and its characteristics, we inserted these cells into the brain of nude rats. Consistent with the in vitro data, a rapidly growing large tumor developed in these rats in just 8 to 10 days, whereas in the control group, the tumor was much smaller. Analysis of sections from U251 O tumors at 10 days and from the tumor induced by mock-transfected U251 that reached comparative high volumes (18 days) revealed that U251 O tumors have high mitotic figures, consistent with increased cell proliferation. Both tumors have similar vascular density, suggesting that U251 O was not only fast growing but also capable of simultaneously creating a vascular network to permit this accelerated growth. This is consistent with the view that the CYP4A1–20-HETE can promote and/or regulate angiogenesis (Chen et al., 2005; Guo et al., 2007). These data show that high endogenous 20-HETE synthase in U251, a human glioma cell line, leads to a fast-growing tumor in vivo.
These are the first studies dealing with CYP4A enzymes and a human glioma cell line, and their clinical relevance is not clear yet. One possible explanation for this association is that elevated production of 20-HETE in tumors might stimulate the cell replicating machinery, leading to a marked increase in cell proliferation in vitro and the growth of tumors in vivo. Further studies are needed to ascertain whether or not 20-HETE synthesis contributes to tumor growth in humans. This would be clinically important because CYP4A/4F activity can be readily inhibited.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
Part of this work were previously presented as follows: Guo AM, Edwards PA, Falck JR, Roman RJ, Jafari-Khouzani K, and Scicli GA (2008) Overexpression of CYP4A1-20-HETE in U251 glioma cell induces a hyperproliferative phenotype in vitro and rapidly growing tumors in vivo. 10th Annual Winter Eicosanoid Conference; 2008 Mar 9–12; Baltimore, MD; and Guo AM, Roman RJ, Falck JR, Jafari-Khouzani K, Edwards PA, and Scicli GM (2008) Overexpression of CYP4A1-20-HETE in U251 glioma cell induces hyperproliferative phenotypes in vitro and in vivo; 2008 Experimental Biology Annual Meeting; 2008 Apr 5–9; San Diego, CA.
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
ABBREVIATIONS: AA, arachidonic acid; P450, cytochrome P450; 20-HETE, 20-hydroxyeicosatetraenoic acid; VEGF, vascular endothelial growth factor; DMEM, Dulbecco's modified Eagle's medium; siRNA, small interfering RNA; HET0016, N-hydroxy-N'-(4-butyl-2-methylphenyl)-formamidine; DDMS, N-methylsulfonyl-12,12-dibromododec-11-enamide; 20-HEDE, 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid; ERK, extracellular signal-regulated kinase; DHE, dihydroethidium; FITC, fluorescein isothiocyanate; DAPI, 4,6-diamidino-2-phenylindole; MRI, magnetic resonance imaging; ROI, region(s) of interest; SI, signal intensity; PEG-SOD, polyethylene glycol-superoxide dismutase; U0126, 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophynyltio)butadiene; ROS, reactive oxygen species; MAPK, mitogen-activated protein kinase; 6,15-HEDGE, N-[20-hydroxyeicosa-6(Z),15(Z)-dienoyl]glycine.
Address correspondence to: Dr. Austin M. Guo, Eye Care Services, Henry Ford Health System, One Ford Place, 4 D, Detroit, MI 48202-3450. E-mail: mguo1{at}hfhs.org
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Capdevila JH and Falck JR (2002) Biochemical and molecular properties of the cytochrome P450 arachidonic acid monooxygenases. Prostaglandins Other Lipid Mediat 68–69: 325-344.[CrossRef][Medline]
Chen P, Guo M, Wygle D, Edwards PA, Falck JR, Roman RJ, and Scicli AG (2005) Inhibitors of cytochrome P450 4A suppress angiogenic responses. Am J Pathol 166: 615-624.
Cheng J, Ou JS, Singh H, Falck JR, Narsimhaswamy D, Pritchard KA Jr, and Schwartzman ML (2008) 20-Hydroxyeicosatetraenoic acid causes endothelial dysfunction via eNOS uncoupling. Am J Physiol Heart Circ Physiol 294: H1018-H1026.
Gebremedhin D, Lange AR, Lowry TF, Taheri MR, Birks EK, Hudetz AG, Narayanan J, Falck JR, Okamoto H, Roman RJ, et al. (2000) Production of 20-HETE and its role in autoregulation of cerebral blood flow. Circ Res 87: 60-65.
Gordon GR, Mulligan SJ, and MacVicar BA (2007) Astrocyte control of the cerebrovasculature. Glia 55: 1214-1221.[CrossRef][Medline]
Graham RA, Goodwin B, Merrihew RV, Krol WL, and Lecluyse EL (2006) Cloning, tissue expression, and regulation of beagle dog CYP4A genes. Toxicol Sci 92: 356-367.
Guo AM, Arbab AS, Falck JR, Chen P, Edwards PA, Roman RJ, and Scicli AG (2007) Activation of VEGF through ROS mediates 20-HETE-induced endothelial cell proliferation. J Pharmacol Exp Ther 321: 18-27.
Guo M, Roman RJ, Falck JR, Edwards PA, and Scicli AG (2005a) Human U251 glioma cell proliferation is suppressed by HET0016, a selective inhibitor of CYP4A. J Pharmacol Exp Ther 315: 526-533.
Guo M, Roman RJ, Fenstermacher JD, Brown SL, Falck JR, Arbab AS, Edwards PA, and Scicli AG (2005b) 9L gliosarcoma cell proliferation and tumor growth in rats are suppressed by HET0016, a selective inhibitor of CYP4A. J Pharmacol Exp Ther 317: 97-108.[CrossRef][Medline]
Hoelzinger DB, Demuth T, and Berens ME (2007) Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J Natl Cancer Inst 99: 1583-1593.
Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, and Batchelor TT (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8: 610-622.[Medline]
Liang CJ, Ives HE, Yang CM, and Ma YH (2008) 20-HETE inhibits the proliferation of vascular smooth muscle cells via transforming growth factor-beta. J Lipid Res 49: 66-73.
Malumbres M and Barbacid M (2005) Mammalian cyclin-dependent kinases. Trends Biochem Sci 30: 630-641.[CrossRef][Medline]
Malumbres M, Sotillo R, Santamaría D, Galán J, Cerezo A, Ortega S, Dubus P, and Barbacid M (2004) Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 118: 493-504.[CrossRef][Medline]
Medhora M, Dhanasekaran A, Gruenloh SK, Dunn LK, Gabrilovich M, Falck JR, Harder DR, Jacobs ER, and Pratt PF (2007a) Emerging mechanisms for growth and protection of the vasculature by cytochrome P450-derived products of arachidonic acid and other eicosanoids. Prostaglandins Other Lipid Mediat 82: 19-29.[CrossRef][Medline]
Medhora M, Dhanasekaran A, Gruenloh SK, Dunn LK, Gabrilovich M, Falck JR, Harder DR, Jacobs ER, and Pratt PF (2007b) Emerging mechanisms for growth and protection of the vasculature by cytochrome P450-derived products of arachidonic acid and other eicosanoids. Prostaglandins Other Lipid Mediat 82: 19-29.[CrossRef][Medline]
Medhora MM, Chen Y, Gruenloh SK, Harland D, Bodiga S, Zielonka J, Gebremedhin D, Gao Y, Falck JR, Anjaiah S, et al. (2008) 20-HETE increases superoxide production and activates NADPH oxidase in pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol 294: L902-L911.
Meloche S and Pouyssegur J (2007) The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 26: 3227-3239.[CrossRef][Medline]
Metea MR and Newman EA (2006) Glial cells dilate and constrict blood vessels: a mechanism of neurovascular coupling. J Neurosci 26: 2862-2870.
Metea MR and Newman EA (2007) Signalling within the neurovascular unit in the mammalian retina. Exp Physiol 92: 635-640.
Nguyen X, Wang MH, Reddy KM, Falck JR, and Schwartzman ML (1999) Kinetic profile of the rat CYP4A isoforms: arachidonic acid metabolism and isoform-specific inhibitors. Am J Physiol Regul Integr Comp Physiol276: R1691-R1700.
Nilakantan V, Maenpaa C, Jia G, Roman RJ, and Park F (2008) 20-HETE-mediated cytotoxicity and apoptosis in ischemic kidney epithelial cells. Am J Physiol Renal Physiol 294: F562-F570.
Peddinti R, Zeine R, Luca D, Seshadri R, Chlenski A, Cole K, Pawel B, Salwen HR, Maris JM, and Cohn SL (2007) Prominent microvascular proliferation in clinically aggressive neuroblastoma. Clin Cancer Res 13: 3499-3506.
Pelicano H, Carney D, and Huang P (2004) ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 7: 97-110.[CrossRef][Medline]
Reiners JJ Jr, Clift R, and Mathieu P (1999) Suppression of cell cycle progression by flavonoids: dependence on the aryl hydrocarbon receptor. Carcinogenesis 20: 1561-1566.
Roman RJ (2002) P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82: 131-185.
Sacerdoti D, Gatta A, and McGiff JC (2003) Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology. Prostaglandins Other Lipid Mediat 72: 51-71.[CrossRef][Medline]
Sun CW, Falck JR, Harder DR, and Roman RJ (1999) Role of tyrosine kinase and PKC in the vasoconstrictor response to 20-HETE in renal arterioles. Hypertension 33: 414-418.
Ueda S, Masutani H, Nakamura H, Tanaka T, Ueno M, and Yodoi J (2002) Redox control of cell death. Antioxid Redox Signal 4: 405-414.[CrossRef][Medline]
Yoon S and Seger R (2006) The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24: 21-44.[Medline]
Yu M, Cambj-Sapunar L, Kehl F, Maier KG, Takeuchi K, Miyata N, Ishimoto T, Reddy LM, Falck JR, Gebremedhin D, et al. (2004) Effects of a 20-HETE antagonist and agonists on cerebral vascular tone. Eur J Pharmacol 486: 297-306.[CrossRef][Medline]
Zhao X and Imig JD (2003) Kidney CYP450 enzymes: biological actions beyond drug metabolism. Curr Drug Metab 4: 73-84.[CrossRef][Medline]
This article has been cited by other articles:
|
|
 |
|
  T. Akbulut, K. R. Regner, R. J. Roman, E. D. Avner, J. R. Falck, and F. Park 20-HETE activates the Raf/MEK/ERK pathway in renal epithelial cells through an EGFR- and c-Src-dependent mechanism Am J Physiol Renal Physiol, September 1, 2009; 297(3): F662 - F670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Guo, G. Scicli, J. Sheng, J. C. Falck, P. A. Edwards, and A. G. Scicli 20-HETE can act as a nonhypoxic regulator of HIF-1{alpha} in human microvascular endothelial cells Am J Physiol Heart Circ Physiol, August 1, 2009; 297(2): H602 - H613. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Xu, Y. He, M. Vokurkova, and R. M. Touyz Endothelial Cells Negatively Modulate Reactive Oxygen Species Generation in Vascular Smooth Muscle Cells: Role of Thioredoxin Hypertension, August 1, 2009; 54(2): 427 - 433. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
